Abstract: Background. Several factors contribute to the documented racial disparity in head and neck cancer, among which are socioeconomic status, access to care, and biologic factors.
Head and neck squamous cell carcinoma (HNSCC) represented around 3% of all newly diagnosed cancers in the United States in 2009. 1 The American Cancer Society estimated that 49,260 cases will be diagnosed with and 11,480 patients will die of cancer of the oral cavity, pharynx, and larynx in 2010. 1 Studies have shown differences in HNSCC in survival between whites and African-Americans. Although there are minor differences in incidence between the two races, 2 there is a large disparity in mortality rates. Oral cavity and oropharyngeal cancer mortality in the white population was 3.7 per 100,000 men compared with 6.5 per 100,000 African-American men from 2002 to 2006. 3 Mean survival time also varied significantly by ethnicity. In the United States, 1-year overall survival for HNSCC is 84%, and 5-year survival is 59% (58% for males and 62% for females), but African-Americans' 5-year overall survival is 39.5% (34% for males and 52% for females). 4 Several possible reasons for such outcome differences among racial groups have been proposed. [5] [6] [7] [8] [9] A recent meta-analysis of oral cavity and oropharyngeal cancer incidence by Conway et al 10 reported that head and neck cancer risk was associated with low educational attainment, low occupational social class, and lower income. A lower socioeconomic status among minorities has been thought of as 1 of the possible causes for health disparity and has been associated with less access to health care, less likelihood of being insured, and more advanced stages at presentation compared with patients of higher socioeconomic class. A previous study regarding HNSCC showed that 13% of African-Americans did not have health insurance compared with 1.5% of Hispanics and 0.6% of whites. 9 Other published data have also shown that African-American patients with oral cancer have later presentations than their white counterparts. 11 Although fewer studies have evaluated the independent effect of socioeconomic status 4, 7, 9, [12] [13] [14] [15] [16] or access to care 7, 9, 15 on overall or disease-free survival among African-Americans, none of these studies has investigated the role of both socioeconomic and insurance status on outcome. A recent study reported that overall survival in patients diagnosed with head and neck cancer was worse for blacks compared with whites; such disparity was observed only for oropharyngeal tumors and was dependent on a low prevalence of human papillomavirus (HPV)-positive tumors among black subjects. 17 The study included cases diagnosed with late stage disease only (106 white, 95 black), and a small number of black cases was included in the race-stratified analysis in accord with HPV status (n ¼ 31). Furthermore, the reported hazard ratios (HRs) were not adjusted for confounders such as age, stage, and socioeconomic and insurance status. In this study, we will add to previous literature on survival disparities by reporting findings from a retrospective analysis of consecutive incident head and neck cancer cases nonselected on disease stage, from a tertiary care cancer center. Unique to the study presented is analysis regarding socioeconomic classification, insurance status, and TNM classification. This study will test whether differences in disease outcome remain when tumor stage, socioeconomic status, and access to health care are considered simultaneously.
PATIENTS AND METHODS
Study Population. The study population consisted of patients who were diagnosed with primary HNSCC. Patients with recurrent and/or second primary tumors were excluded. A cohort study design was used, consisting of all consecutive African-American patients (n ¼ 87) diagnosed or receiving the first course of treatment at the University of Pittsburgh Medical Center (Pittsburgh, PA) from January 1987 to October 2007, and a random sample of white patients (n ¼ 261) who were frequency matched to African-Americans 3:1 by age category (<40, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, and 80-84 years) and smoking dose (never smoker; <10 pack-year or <1 pack-per-day or <10 years smoker, >10 pack-year or >1 pack-per-day or >10 years smoker; and smoker, dose unknown and unknown smoking status), selected from a larger cohort of 2,016 whites diagnosed or receiving the first course of treatment at the same facility during the same time frame. To achieve the 3:1 matching, all black (n ¼ 87) and white (n ¼ 2,016) cases were stratified by age and smoking dose and, within each strata, 3 white patients were randomly selected (using a random number generator) for each black patient. The majority of patients (n ¼ 317) were also included in a previous study on cancer survival in accord with insurance status. 18 All of the tumors were biopsy-proven, arising in the oral cavity, pharynx, or larynx. The study was exempt approved by the University of Pittsburgh Institutional Review Board.
Data Collection. Clinical and demographic data for patients diagnosed or treated for head and neck cancer were recorded in the University of Pittsburgh Head and Neck Oncology Registry. Clinical information related to the patients' tumors, vital status, and treatment was gathered prospectively by the Head and Neck Oncology Registry following initial diagnosis and was regularly updated to reflect the patients' status at the most recent follow-up visit. The sources of these data are patient medical records, the University of Pittsburgh Medical Center (UPMC) Network Cancer Registry, and the Social Security Death Index (SSDI).
Data on patient health insurance at the time of diagnosis were obtained via the UPMC billing system as previously described. 18 Insurance status was categorized as private, Medicaid, uninsured, Medicare, and Veterans Affairs. Some patients who were uninsured at the time of diagnosis subsequently enrolled in Medicaid to cover their treatment expenses and could not be distinguished in this dataset; therefore, uninsured and Medicaid enrollees were combined. The Medicare classification was further subdivided into patients younger than 65 years of age (Medicare disability) and those 65 years or older. All of the data included in this study (clinical, demographic, and health insurance) were obtained as a de-identified dataset.
Statistical Analysis. Modified Nakao and Treas occupational prestige scores (Socioeconomic Index [SEI]) 19 were used to produce an indicator of socioeconomic status based on self-reported occupation during working years; patients were categorized by occupational prestige score as unemployed/disabled (0), 0 < SEI < 50, 50 < SEI < 100. An additional category was added to include omemakers, who were not accounted for by the original Nakao and Treas scoring system. Alcohol use was classified as never; 6 drinks/week; 7-14 drinks/week; >14 drinks/week; and drinker, intensity unknown. Cigarette smoking was classified as never, <10 pack-year or <1 pack-per-day or <10 years smoker, >10 pack-year or >1 pack-perday or >10 years smoker, and smoker, dose unknown. Use of other types of tobacco included all noncigarette forms of tobacco (pipe, cigar, chew) and was coded dichotomously as ever versus never use.
Tumor site was the primary site of the initial tumor, categorized by ICD-10 site codes based on the American Joint Committee on Cancer (AJCC) staging manual (6th edition) guidelines 20 as oral cavity (C00.0-C00.6, C00.8, C00.9, C02.0-C02.3, C02.8-C03.1, C03.9-C04.1, C04.8-C05.0, C05.8-C06.2, C06.8, C06.9), pharynx (C01.9, C02.4, C05.1, C05.2, C09.0, C09.1, C09.8-C10.0, C10.2-C10.4, C10.8-C11.3, C11.8, C11.9, C12.9-C13.2, C13.8-C14.2, C14.8), or larynx (C10.1, C32.0-C32.3, C32.8, C32.9). Stage at diagnosis was categorized as stage I, II, III, or IV, in accord with the AJCC staging for head and neck cancer. 20 The AJCC stage group was classified based on pathological TNM classification and, when not available, clinical TNM classification was used. Treatment was categorized as surgery only, radiation and/or chemotherapy only, or surgery and radiation and/or chemotherapy. Three patients who refused treatment were grouped with those for which treatment was unknown. The primary outcomes of interest in this study were overall and relapse-free survival by race. The follow-up time for overall survival was defined as the time from initial diagnosis of the primary tumor to death or last contact if the patient was still alive. The follow-up time for relapse-free survival was defined as the time from initial diagnosis of the primary tumor to recurrence, development of a second primary, or metastasis or last contact if the patient remained relapse-free. For relapse-free survival, patients who died without recurrence were considered censored. The presence of lymph node involvement and advanced stage disease at diagnosis were evaluated as secondary outcomes of interest.
Descriptive statistics were generated for demographic and clinical variables by race, using Fisher's exact test to identify differences between black and white subjects. Kaplan-Meier survival functions were produced for overall and relapse-free survival. Differences in survival by race were tested using the Wilcoxon log-rank test. Multivariable Cox proportional hazards models were developed for overall and relapse-free survival, with race as the primary independent variable of interest. The models were adjusted for age, sex, family history of cancer, socioeconomic status, insurance status at diagnosis, alcohol use, any tobacco use (cigarette and noncigarette forms of tobacco), tumor site, stage at diagnosis, and treatment modality. Proportional hazards assumptions were formally tested using an approach based on scaled Schoenfeld's residuals. 21 Separate multivariable logistic regression models were used to assess the association of race with lymph node involvement and stage at diagnosis, respectively, for all sites and by specific site (oral cavity, pharynx, and larynx). Stage was categorized as advanced-stage (AJCC stage group III or group IV) versus early-stage disease (AJCC stage group I or group II). Lymph node involvement was classified as the presence (N1-N3) versus absence (N0) of positive lymph nodes at diagnosis. The primary predictor in the model was race; other covariates in the model included age (<61 year vs 61 years), any tobacco use (ever vs never), sex, family history of cancer, socioeconomic status (uninsured/disabled, 0 < SEI 50, 50 < SEI 100, homemaker), insurance status (uninsured/disabled, insured), alcohol use (ever vs never), and primary tumor site. Model fit was assessed using the Hosmer and Lemeshow goodness-of-fit test, 22 and was considered a poor fit if p .05. All statistical analyses were performed using Stata 10 software (StataCorp LP, College Station, TX).
RESULTS
Demographic and Clinical Characteristics. The description of the patient population (n ¼ 348) is provided in Table 1 . The mean age was 61 years old (range: 33-84 years); the majority of cases were >10 pack-year or >1 pack-per-day or >10 years smoker (54%); few cases used other types of tobacco. Black patients were more likely to be identified as unemployed or disabled and less likely to be in the higher socioeconomic classes (SEI > 50). Blacks were also less likely to have private insurance and more likely to have Medicaid/uninsured or Medicare disability, compared with whites. Factors such as sex distribution, family history of cancer, alcohol consumption, and other tobacco use were not different between the 2 races. There were differences in cancer characteristics (Table 2) ; black patients were significantly more likely than whites to develop laryngeal cancers (44.8% vs 30.7%; p ¼ .049), and to be diagnosed with stage IV disease (59.0% vs 44.0%; p ¼ .045). Although lymph node involvement at diagnosis and tumor grade were not statistically significantly different with respect to race, white patients were more likely to be treated with surgery plus radiation and/or chemotherapy, whereas black patients were more likely to be treated with radiation and/or chemotherapy only. Among the patients that refused treatment, all of them were black: 3 of 87 black patients (3.4%) or 3 of 386 of the entire cohort (0.9%).
After adjusting for age, sex, family history of cancer, tobacco use, alcohol use, socioeconomic status, insurance status, and tumor site, the relative odds of being diagnosed with advanced stage disease was nonstatistically significantly increased for blacks compared with whites (adjusted odds ratio [AdjOR] ¼ 1.47; 95% confidence interval [CI]: 0.82-2.65) ( Table  3) . Blacks with oral cavity tumors were almost 4-fold more likely to be diagnosed with advanced stage disease compared with whites (AdjOR ¼ 3.60, 95% CI: 0.97-13.41), whereas lymph node involvement in oral cavity tumors was not associated with race. There were no significant differences in disease stage and lymph node involvement with respect to race for cases diagnosed with pharyngeal or laryngeal cancers. The odds ratio for lymph node involvement for blacks compared with whites with laryngeal cancer was not statistically significantly increased (AdjOR ¼ 2.26, 95% CI: 0.92-5.61).
Overall and Relapse-free Survival. The median follow-up for the cohort was 24.4 months (10th percentile: 5.4 months; 90th percentile: 82.8 months), during which there were 156 deaths among 348 at-risk patients. For relapse-free survival, the median followup was 16.9 months (10th percentile: 4.2 months; 90th percentile: 73.1 months), with 148 recurrences, second primary, or metastasis among 348 at-risk patients.
The unadjusted overall and relapse-free KaplanMeier 5-year survival curves are presented in Figure  1 and Figure 2 , respectively. There was no difference between blacks and whites for overall survival (p ¼ .937). However, blacks had borderline poorer 5-year relapse-free survival relative to that of whites (p ¼ .072). The multivariable Cox proportional hazards models (Table 4 ) shows a marginal association between self-reported African-American ancestry and relapse-free survival (adjusted hazard ratio [AdjHR] ¼ 1.47, 95% CI: 0.99-2.18), but not for overall survival (AdjHR ¼ 0.96, 95% CI: 0.64-1.45). Decreased overall survival was independently associated with being unemployed or disabled, having Medicaid or no insurance; there was also a trend in decreased survival with increasing stage at diagnosis; decreased relapse-free survival was independently associated with treatment via radiation and/or chemotherapy only. When cases were stratified with respect to tumor site, there was no difference in overall and relapse-free survival between blacks and whites diagnosed with oral cavity or pharyngeal tumors (data not shown). In contrast, the risk of recurrence second primary or metastasis for black patients with laryngeal tumors was statistically significantly increased compared with that for white patients (AdjHR ¼ 3.36, 95% CI: 1.62-7.00).
DISCUSSION
This study evaluates the clinical characteristics of patients with head and neck cancer with respect to race and suggests that after matching for smoking dose and age, and adjusting for socioeconomic status and insurance status, patients with cancers of the oral cavity and larynx with self-defined African ancestry are more likely to be diagnosed with advanced stage disease. Since primary risk factors for head and neck cancer are tobacco and alcohol, [23] [24] [25] [26] [27] all of the cases included in this study were matched on smoking dose, to account for the effect of smoking in the study design. Alcohol use was similarly distributed between black and white patients. The analysis was also adjusted for socioeconomic status and access to care by using insurance status as a surrogate. Therefore, none of these factors should have significantly contributed to the observed differences in stage with race. Shiboski et al 11 reported somewhat similar findings; AfricanAmericans were diagnosed with a significantly higher proportion of tongue cancer compared with that of whites, which had spread to a regional node or to a distant site; however, these data were not adjusted for socioeconomic and insurance status or smoking. 11 In our study, black patients with oral cavity tumors were more likely to present with advanced-stage disease, but did not have an increased likelihood of nodal involvement. This suggests that the increased likelihood of advanced stage disease observed for blacks with oral cavity tumors may not necessarily be attributed to differences in behavioral risk factors, poor socioeconomic status, or access to care. In contrast to cases of oral cavity tumors, black and white patients diagnosed with tumors of the pharynx or larynx did not significantly differ in the disease stage or nodal involvement, although black patients were significantly more likely than whites to develop laryngeal cancers. Studies have reported that blacks are less likely to stop smoking and are more likely to smoke mentholated cigarettes compared with whites. 28, 29 Smoking mentholated cigarettes results in deeper and longer inhalations, 30, 31 which would allow tobacco smoke to reach the larynx. This may also help to explain the reason that blacks are more likely to develop laryngeal cancers compared with whites. Nevertheless, we cannot rule out the possibility that host factors related to tobacco metabolism may also play a role in the observed tumor site-specific risk and advanced-stage disease between blacks and whites.
Arbes Jr et al 5 evaluated disease-specific survival for 1,165 blacks and 7,338 whites diagnosed with either oral cavity or pharyngeal cancer. After adjusting for age, geographic area, socioeconomic status, stage, and treatment, the study reported no significant difference with respect to race (HR ¼ 1.1, 95% CI ¼ 0.9-1.4). Our study reported similar results after additional adjustments for smoking and insurance status. In addition, we report that the risk of recurrence, second primary, or metastasis was almost 2-fold for blacks compared with that for whites. Differences in treatment modalities between blacks and whites may explain the increased risk of recurrence, second primary, or metastasis among black patients. Murdock and Gluckman 8 examined differences in treatment modalities for HNSCC in 54 African-American and 52 whites, and showed higher incidence of surgical intervention among whites compared with blacks, but did not evaluate relapse-free survival. We observed a higher incidence of surgical intervention among whites; moreover, relapse-free survival was independently associated with treatment by radiation and/or chemotherapy only and was not associated with socioeconomic status or a lack of health insurance.
Although tobacco and alcohol use are primary risk factors for all head and neck tumors, HPV is also thought to be an independent risk factor for most pharyngeal tumors. [32] [33] [34] In a previous study, we reported that patients with HPV-positive tumors have an improved survival and are less likely to develop recurrent tumors; furthermore, the improved survival and recurrence, second primary, or metastasis rate were restricted to tumors diagnosed in the pharynx. 35 A recent study by Chen et al 36 reported that among patients with oropharyngeal cancer, African-Americans and Hispanics had lower overall survival compared with that of white patients, although this study did not include or adjust for socioeconomic or access to care in the analysis, nor evaluate the role of HPV. In our study the contribution of HPV involvement could not be evaluated as well, and this was a limitation. Nevertheless, after adjusting for the covariates in the model there was no difference in the risk of death or recurrence, second primary, or metastasis for black patients diagnosed with oral cavity or pharyngeal tumors, compared with that for white patients. Further research of overall survival and relapse-free survival that include both HPV status and sociodemographic variables are needed to further evaluate racial disparities in head and neck cancer outcomes. Although differences in disease outcome with respect to race may be attributed to a combination of tumor stage, socioeconomic status, and access to health care, our findings suggest that the disparity still exists after adjusting for these factors. The inclusion of biologic markers such as HPV status and the extension of the study to a larger sample of black patients are needed to further evaluate racial disparities in head and neck cancer outcomes.
